Provided by Tiger Trade Technology Pte. Ltd.

CANSINOBIO

26.840
-1.820-6.35%
Volume:3.98M
Turnover:107.82M
Market Cap:6.63B
PE:244
High:28.400
Open:28.260
Low:26.640
Close:28.660
52wk High:55.850
52wk Low:19.220
Shares:247.04M
HK Float Shares:132.67M
Volume Ratio:0.68
T/O Rate:3.00%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.110
ROE:0.82%
ROA:-0.60%
PB:1.14
PE(LYR):244.00
PS:4.59

Loading ...

Movement Alert|CANSINOBIO Rises 14.34% in Regular Trading, Strategic mRNA Tumor Vaccine Partnership with Depushi Bio Announced

Market Focus
·
Aug 26

Movement Alert|CANSINOBIO Rises 6.15% in Regular Trading, Rebounding After Multi-Day Pullback as Broker Flags Severe Undervaluation in mRNA Sector

Market Focus
·
Aug 25

AH Share Premium Rankings: Market Close Update for August 24

Stock News
·
Aug 24

Movement Alert|CANSINOBIO Declines 5.16% in Regular Trading, Profit-Taking Continues After mRNA-Driven Surge

Market Focus
·
Aug 24

AH Share Premium Tracker | August 21 Market Close

Stock News
·
Aug 21

Movement Alert|CANSINOBIO Intraday Decline 7.99%, Pullback Following Previous Sessions Massive mRNA Vaccine-Driven Rally

Market Focus
·
Aug 21

CanSino Biologics' Application for Tetanus Vaccine Approved in China

MT Newswires Live
·
Aug 20

AH Share Premium Ranking Update: August 20 Market Close

Stock News
·
Aug 20

Chinese Vaccine Makers Jump on News of Key Success in Cancer Treatment, CanSino Leads

Reuters
·
Aug 20

CanSino Biologics Surges Over 35% as Analysts See Parallels with Moderna's Vaccine Platform

Stock News
·
Aug 20

CLSA Says CansinoBio Shares Surge as Moderna's mRNA Cancer Vaccine Succeeds in Late-Stage Trial

Stock News
·
Aug 20

HK Movers | Pharma Stocks Surge With 3D Medicines up 68%, CanSino Biologics up 52%

Tiger Newspress
·
Aug 20

Hong Kong Stock Alert: CansinoBio Jumps 15% as mRNA Cancer Vaccine Sector Gets Major Boost

Stock News
·
Aug 20

AH Premium Rankings Unveiled: August 18 Market Close Data

Stock News
·
Aug 18

Dual-Listed Stock Premium Rankings: August 17 Closing Data

Stock News
·
Aug 17

CanSino Biologics Says China's Nmpa Accepts New Drug Application for TD5cp Adolescent and Adult

THOMSON REUTERS
·
Aug 16

CanSino Biologics: Td5cp Vaccine for Adolescents and Adults Accepted for New Drug Review

Stock News
·
Aug 16

CANSINOBIO Receives NMPA Acceptance and Priority Review for Five-Component DTaP Booster Vaccine

Bulletin Express
·
Aug 16

Dual-Listed Stock Premium Ranking: August 14 Market Close

Stock News
·
Aug 14

CANSINOBIO Reports Zero Share Capital Changes for July 2026; 860,000 H-Share Options Remain Outstanding

Bulletin Express
·
Aug 04